What You Should Know:
– Caris Life Sciences® (Caris), the a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the company has closed a senior secured term loan providing up to $400M in capital from OrbiMed and Braidwell. With this funding, Caris has raised approximately $1.7 billion in capital since 2018.
– Caris’ comprehensive molecular profiling approach precisely analyzes DNA (Whole Exome Sequencing), RNA (Whole Transcriptome Sequencing), and protein biomarkers to reveal a patient’s molecular blueprint for selecting the most appropriate therapies. Caris uses highly sophisticated artificial intelligence (AI) and machine learning to identify proprietary signatures to classify cancer at the molecular level and predict patient response.
– Caris will use the proceeds to repay outstanding debt, enhance its pioneering precision medicine platform, and for general corporate purposes. Caris has been the leading innovator in molecular profiling since it was founded in 2008, with a molecular database of over 455,000 tumor profiles to date, including more than 350,000 profiles with matched molecular data and clinical outcomes.
